Expression of dihydrodiol dehydrogenase in the resected stage I non-small cell lung cancer

Oncology Reports

Volumn 9, Issue 3, 2002, Pages 515-519

  Chen, Chih Yi ^a   Hsu, Chung Ping ^b   Hsu, Nan Yung ^c   Shih, Chih Shiun ^c   Lin, Tze Yi ^c   Chow, Kuan Chih ^c  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Dihydrodiol dehydrogenase; Non small cell lung cancer; Stage I

Indexed keywords

DIHYDRODIOL DEHYDROGENASE; OXIDOREDUCTASE; TRANS-1,2-DIHYDROBENZENE-1,2-DIOL DEHYDROGENASE;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; CELL DIFFERENTIATION; DISEASE FREE SURVIVAL; ENZYMOLOGY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; MORTALITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOKING;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIFFERENTIATION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; OXIDOREDUCTASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SMOKING;

EID: 0036582569     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.9.3.515     Document Type: Article

References (31)

1. Wu CG, Hakvoort TB, Lamers WH and Chamuleau RA: Isolation of up- and down-regulated cDNAs associated with hepatocellular carcinoma by a subtraction-enhanced display technique. Biochim Biophys Acta 1315: 169-175, 1996. (Pubitemid 26128325)
2. Velculescu VE, Zhang L, Vogelstein B and Kinzler KW: Serial analysis of gene expression. Science 270: 484-487, 1995.
3. Maeda S, Otsuka M, Hirata Y, Mitsuno Y, Yoshida H, Shiratori Y, Masuho Y, Muramatsu M, Seki N and Omata M: cDNA micro-array analysis of Helicobacter pylori-mediated alteration of gene expression in gastric cancer cells. Biochem Biophys Res Commun 284: 443-449, 2001. (Pubitemid 32917996)
4. Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, Emmert-Buck MR, Roth MJ, Petricoin EF III and Liotta LA: Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20: 1981-1989, 2001. (Pubitemid 32458030)
5. Liang P, Averboukh L and Pardee AB: Distribution and cloning of eukaryotic mRNAs by means of differential display: refinements and optimization. Nucleic Acids Res 21: 3269-3275, 1993. (Pubitemid 23230499)
6. Hsu NY, Ho HC, Chow KC, Lin TY, Shin CS, Wang LS and Tsai CM: Overexpression of Dihydrodiol Dehydrogenase as a prognostic marker of non-small cell lung cancer. Cancer Res 61: 2727-2731, 2001.
7. Vogel K, Bentley P, Piatt KL and Oesch F: Rat liver cytoplasmic dihydrodiol dehydrogenase. J Biol Chem 255: 9621-9625, 1980.
8. Cheng KC: Molecular cloning of rat liver 3α-hydroxysteroid dehydrogenase and related enzymes from rat liver, kidney and lung. J Steroid Biochem Mol Biol 43: 1083-1088, 1992.
9. Burczynski ME, Harvey RG and Penning TM: Expression and characterization of four recombinant human dihydrodiol dehydrogenase isoforms: oxidation of trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene to the activated o-quinone metabolite benzo[a]pyrene-7,8-dione. Biochemistry 37: 6781-6790, 1998. (Pubitemid 28228113)
10. Hara A, Matsuura K, Tamada Y, Sato K, Miyabe Y, Deyashiki Y and Ishida N: Relationship of human liver dihydrodiol dehydrogenases to hepatic bile-acid-binding protein and an oxidoreductase of human colon cells. Biochem J 313: 373-376, 1996. (Pubitemid 26030122)
11. Mountain CF: Revisions in the international system for staging lung cancer. Chest 111: 1710-1717, 1997.
12. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170, 1966.
13. Shou M, Harvey RG and Penning TM: Contribution of dihydrodiol dehydrogenase to the metabolism of (±)-trans-l,8-dihydroxy-7,8- dihydrobenzo[a]pyrene in fortified rat liver subcellular fractions. Carcinogenesis 13: 1575-1582, 1992.
14. Dresler CM, Fratelli C, Babb J, Everley L, Evans AA and Clapper ML: Gender differences in genetic susceptibility for lung cancer. Lung Cancer 30: 153-160, 2000. (Pubitemid 32007871)
15. Shen H, Kauvar L and Tew KD: Importance of glutathione and associated enzymes in drug response. Oncol Res 9: 295-302, 1997. (Pubitemid 127825983)
16. Penning TM and Sharp RB: Characterization of dihydrodiol dehydrogenase in human liver and lung. Carcinogenesis 11: 1203-1208, 1990. (Pubitemid 20236284)
17. Burczynski ME, Lin HK and Penning TM: Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res 59: 607-614, 1999. (Pubitemid 29076058)
18. Parkin DM: Epidemiology of cancer: global patterns and trends. Toxicol Lett 102-103: 227-234, 1998.
19. Kubik A, Plesko I and Reissigova J: Prediction of lung cancer mortality in four Central European countries, 1990-2009. Neoplasma 45: 60-67, 1998.
20. Hirao T, Nelson H.H, Ashok TD, Wain JC, Mark EJ, Christiani DC, Wiencke JK and Kelsey KT: Tobacco smoke-induced DNA damage and an early age of smoking initiation induce chromosome loss at 3p21 in lung cancer. Cancer Res 61: 612-615, 2001. (Pubitemid 32128623)
21. Olencki T, Finke J, Tubbs R, Elson P, McLain D, Herzog P, Budd GT, Gunn H and Bukowski RM: Phase 1 trial of subcutaneous IL-6 in patients with refractory cancer: clinical and biologic effects. J Immunother 23: 549-556, 2000.
22. Sugiyama Y, Kato M, Chen FA, Williams SS, Kawaguchi Y, Miya K, Jong YS, Mathiowitz E, Egilmez NK and Bankert RB: Human inflammatory cells within the tumor microenvironment of lung tumor xenografts mediate tumor growth suppression in situ that depends on and is augmented by interleukin-12. J Immunother 24: 37-45, 2001. (Pubitemid 32101966)
23. Dosaka-Akita H, Hommura F, Mishina T, Ogura S, Shimizu M, Katoh H and Kawakami Y: A risk-stratification model of non-small cell lung cancers using cyclin E, Ki-67, and ras p21: different roles of Gl cyclins in cell proliferation and prognosis. Cancer Res 61: 2500-2504, 2001. (Pubitemid 32691131)
24. Kang Y, Prentice MA, Mariano JM, Davarya S, Linnoila RI, Moody TW, Wakefield LM and Jakowlew SB: Transforming growth factor-beta 1 and its receptors in human lung cancer and mouse lung carcinogenesis. Exp Lung Res 26: 685-707, 2000. (Pubitemid 32044586)
25. Bredin CG, Liu Z, Hauzenberger D and Klominek J: Growth-factor-dependent migration of human lung-cancer cells. Int J Cancer 82: 338-345, 1999. (Pubitemid 29302974)
26. Ax W, Soldan M, Koch L and Maser E: Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem Pharmacol 59: 293-300, 2000. (Pubitemid 30001756)
27. Buccheri G, Ferrigno D, Vola F and Curcio A: Combination chemotherapy with methotrexate, adriamycin, cyclophosphamide and CCNU (MACC) for non-small cell lung cancer. Four-year experience with 92 patients. Oncology 46: 212-216, 1989. (Pubitemid 19160871)
28. Buccheri G and Ferrigno D: A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer. Cuneo Lung Cancer Study Group. Eur J Cancer 30A: 1424-1431, 1994. (Pubitemid 24342999)
29. Beattie CW, Hansen NW and Thomas PA: Steroid receptors in human lung cancer. Cancer Res 45: 4206-4214, 1985. (Pubitemid 16224875)
30. Kaiser U, Hofmann J, Schilli M, Wegmann B, Klotz U, Wedel S, Virmani AK, Wollmer E, Branscheid D, Gazdar AF and Havemann K: Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. Int J Cancer 67: 357-364, 1996. (Pubitemid 26274126)
31. Loprevite M, Favoni RE, De Cupis A, Pirani P, Merlo F, Grossi F and Ardizzoni A: Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity. Int J Oncol 15: 787-792, 1999.